Diabetes without manifest cardiovascular disease: A novel approach in risk stratification and treatment selection

dc.contributor.authorAndari, Emile
dc.contributor.authorArnaout, Mohammad Samir
dc.contributor.authorAzar, Sami T.
dc.contributor.authorChammas, Elie J.
dc.contributor.authorJambart, Sélim
dc.contributor.authorSaleh, Mounzer
dc.contributor.authorNemr, Rita
dc.contributor.authorSarkis, Antoine
dc.contributor.departmentInternal Medicine
dc.contributor.departmentDivision of Cardiology
dc.contributor.departmentDivision of Endocrinology and Metabolism
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:56:45Z
dc.date.available2025-01-24T11:56:45Z
dc.date.issued2020
dc.description.abstractBackground: Cardiovascular disease (CVD), the main macro vascular complication of type 2 diabetes (T2D), increases the risk of death significantly in patients with T2D. Introduction: Most of the patients with T2D do not have obvious CVD symptoms. Due to the paucity of data, CVD screening in asymptomatic patients with T2D remains highly controversial. Methods: This has driven a panel of experts to establish a novel consensus on how to approach patients with T2D at high CVD risk. The panel formulated a stepwise algorithm by which patients with T2D undergo initial risk stratification into low, intermediate and high risk using the ASCVD calculator. In patients with intermediate risk, coronary artery calcium measurement is used to further stratify those patients into new low and high-risk categories. Results and Conclusion: The panel recommends using standard diabetes care in low risk patients and using SGLT2 inhibitors and GLP1 agonists with cardio protective effect, on top of standard care, in high risk individuals. © 2020 Bentham Science Publishers.
dc.identifier.doihttps://doi.org/10.2174/1573399816666200120122929
dc.identifier.eid2-s2.0-85090883713
dc.identifier.pmid31987023
dc.identifier.urihttp://hdl.handle.net/10938/31265
dc.language.isoen
dc.publisherBentham Science Publishers
dc.relation.ispartofCurrent Diabetes Reviews
dc.sourceScopus
dc.subjectCardiovascular disease
dc.subjectDiabetes mellitus
dc.subjectGlp1 agonists
dc.subjectMacrovascular complications
dc.subjectRisk stratification
dc.subjectSglt2 inhibitors
dc.subjectAlgorithms
dc.subjectCalcium
dc.subjectCardiovascular agents
dc.subjectCardiovascular diseases
dc.subjectConsensus
dc.subjectCoronary vessels
dc.subjectDiabetes mellitus, type 2
dc.subjectGlucagon-like peptide-1 receptor
dc.subjectHumans
dc.subjectHypoglycemic agents
dc.subjectMass screening
dc.subjectPatient selection
dc.subjectProtective agents
dc.subjectRisk assessment
dc.subjectSodium-glucose transporter 2 inhibitors
dc.subjectTomography, x-ray computed
dc.subjectSodium glucose cotransporter 2 inhibitor
dc.subjectAntidiabetic agent
dc.subjectCardiovascular agent
dc.subjectGlp1r protein, human
dc.subjectGlucagon like peptide 1 receptor
dc.subjectProtective agent
dc.subjectArticle
dc.subjectCardiovascular risk
dc.subjectCoronary artery
dc.subjectDiabetic patient
dc.subjectHigh risk patient
dc.subjectHuman
dc.subjectIntermediate risk patient
dc.subjectLow risk patient
dc.subjectNon insulin dependent diabetes mellitus
dc.subjectPriority journal
dc.subjectRandomized controlled trial (topic)
dc.subjectScreening
dc.subjectSymptom
dc.subjectAlgorithm
dc.subjectComplication
dc.subjectCoronary blood vessel
dc.subjectDiagnostic imaging
dc.subjectX-ray computed tomography
dc.titleDiabetes without manifest cardiovascular disease: A novel approach in risk stratification and treatment selection
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2020-3577.pdf
Size:
481.04 KB
Format:
Adobe Portable Document Format